Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Scalp Cooling Reduces Alopecia in Women Undergoing Chemotherapy

By HospiMedica International staff writers
Posted on 03 Mar 2017
A new study suggests that using a scalp-cooling device may help reduce hair loss in women with breast cancer receiving chemotherapy.

Researchers at Baylor College of Medicine, Memorial Sloan-Kettering Cancer Center, and other institutions conducted a randomized clinical trial involving 182 women with breast cancer undergoing chemotherapy between December 9, 2013, and September 30, 2016. More...
The study was conducted at seven sites in the United States in order to assess whether a scalp-cooling device is effective at reducing chemotherapy-induced alopecia and assess adverse treatment effects.

Scalp cooling was done 30 minutes prior to and during the chemotherapy infusion, and 90 minutes after each session. The primary efficacy end points were successful hair preservation at the end of four cycles of chemotherapy, as determined by a clinician unaware of treatment assignment, and device safety. Secondary end points included wig use and scores on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (Core 30), the Hospital Anxiety and Depression Scale, and a summary of the Body Image Scale.

At the time of the interim analysis, the researchers found that patients who received scalp cooling were significantly more likely to have reduced hair loss, with 51% of those in the scalp cooling group retaining all their hair, compared with 0% of those in the control group. There were no significant differences in changes in any of the measures of quality of life between the groups. In addition, 54 adverse events were reported in the scalp-cooling group, none of them serious. The study was published on February 14, 2017, in JAMA.

“Among women with stage I to II breast cancer receiving chemotherapy with a taxane, anthracycline, or both, those who underwent scalp cooling were significantly more likely to have less than 50% hair loss after the fourth chemotherapy cycle compared with those who received no scalp cooling,” concluded lead author Julie Nangia, MD, of the Baylor College of Medicine. “Further research is needed to assess longer-term efficacy and adverse effects.”

Chemotherapy may result in hair loss (alopecia), rated by women as one of its most distressing adverse effects. Scalp cooling is hypothesized to work by reducing blood flow to hair follicles and reducing the uptake of chemotherapeutic agents. Modern methods to prevent hair loss use devices that circulate fluid in a cooling cap using refrigeration. A cap is placed on the patient prior to chemotherapy and does not have to be changed or removed until the treatment is completed.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Pediatric Mask
Respire SOFT
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The study is the first to demonstrate a single nanomaterial platform that combines rapid blood clotting, activation of the body’s own latent growth factors, recruitment of bone-forming stem cells and enhanced bone regeneration. (Image Credit: Stef Zingsheim/University of Sydney)

Nanobone Material Activates Natural Repair Signals to Regrow Bone

Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. Repairing the resulting jawbone... Read more

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.